AOD-9604
C-terminal hGH fragment (176-191). Originally developed as a fat-burning analog of growth hormone without GH's metabolic side effects.
This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.
Synthetic 16-amino acid sequence. Phase 2b trials in Australia (Metabolic Pharmaceuticals) for obesity failed primary endpoint. Often marketed as joint/cartilage adjunct based on limited preclinical data. TGA-listed in Australia for compounding; FDA does not recognize as a drug.
Failed phase 2b for primary obesity endpoint. Cartilage/joint claims rest on a few preclinical studies. Treat as speculative.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
- DMechanistic / anecdotal
AOD-9604 — primary mechanism: c-terminal hgh fragment (176-191). originally developed as a fat-burning analog of growth hormone without gh's metabolic side effects.
1 supporting referencesVerified 5d ago
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: 300-500 µg · daily, subcutaneous
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
Research-grey in US; TGA-listed in AU